Crossmark

Analysis of the androgen receptor–regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression

Crossref DOI link: https://doi.org/10.1038/s41588-018-0120-1

Published Online: 2018-05-28

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Yajia

Pitchiaya, Sethuramasundaram

Cieślik, Marcin

Niknafs, Yashar S.

Tien, Jean C.-Y.

Hosono, Yasuyuki

Iyer, Matthew K.

Yazdani, Sahr

Subramaniam, Shruthi

Shukla, Sudhanshu K.

Jiang, Xia

Wang, Lisha

Liu, Tzu-Ying

Uhl, Michael https://orcid.org/0000-0002-9563-4991
Gawronski, Alexander R.

Qiao, Yuanyuan

Xiao, Lanbo

Dhanasekaran, Saravana M.

Juckette, Kristin M.

Kunju, Lakshmi P.

Cao, Xuhong

Patel, Utsav

Batish, Mona

Shukla, Girish C.

Paulsen, Michelle T.

Ljungman, Mats

Jiang, Hui https://orcid.org/0000-0003-2718-9811
Mehra, Rohit

Backofen, Rolf https://orcid.org/0000-0001-8231-3323
Sahinalp, Cenk S.

Freier, Susan M.

Watt, Andrew T.

Guo, Shuling

Wei, John T.

Feng, Felix Y.

Malik, Rohit

Chinnaiyan, Arul M. https://orcid.org/0000-0001-9282-3415
License Information

Text and Data Mining valid from 2018-05-28
More Information

Article History

Received: 7 February 2017

Accepted: 23 March 2018

First Online: 28 May 2018

Competing interests

: The University of Michigan has filed a patent on lncRNAs as biomarkers of cancer, and A.M.C., R. Malik, Y.Z., M.C. and S.P. are named as co-inventors. A.M.C. is a co-founder of LynxDx, which is developing lncRNA biomarkers. S.M.F., A.T.W. and S.G. are employees of Ionis Pharmaceuticals, which developed the ASOs against ARLNC1 that were used in this study.